SCHEMBL4418150

SCHEMBL4418150

O=c1n(C2CCNCC2)c2ccccc2n1S(=O)(=O)c1ccc2ccccc2c1

nearest known ligand 0.56

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
HTR6 P50406 7/20 0.56
PKM P14618 3/20 0.51
MCOLN3 Q8TDD5 3/20 0.43
LMNA P02545 3/20 0.43
ALDH1A1 P00352 3/20 0.43
TSHR P16473 2/20 0.43
USP2 O75604 1/20 0.43
GAA P10253 1/20 0.43
SLC6A2 P23975 3/20 0.42
SLC6A4 P31645 3/20 0.42
SLC6A3 Q01959 1/20 0.41
KCNH2 Q12809 1/20 0.41
AKR1C3 P42330 1/20 0.40
AKR1C1 Q04828 1/20 0.40
KDM4E B2RXH2 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13006378 0.77 HTR6 (0.40) HTR6SLC6A2SLC6A4
SCHEMBL4432215 0.74 MAPT (0.41) HTR6LMNAALDH1A1TSHRGAA
SCHEMBL4416818 0.74 HTR6 (0.39) HTR6USP2
SCHEMBL4425141 0.74 PKM (0.42) HTR6PKMUSP2SMN1; SMN2
SCHEMBL4424954 0.74 HTR6 (0.42) HTR6LMNAALDH1A1TSHRSMN1; SMN2
SCHEMBL4432222 0.74 HTR6 (0.45) HTR6LMNAALDH1A1TSHRAKR1C3
SCHEMBL4420468 0.73 PRKCG (0.41) HTR6LMNAALDH1A1USP2SLC6A4
SCHEMBL12341270 0.73 PKM (0.71) PKMMCOLN3LMNAALDH1A1TSHR
SCHEMBL4423058 0.73 POLB (0.36) HTR6LMNA
SCHEMBL4420697 0.73 HTR6 (0.32) HTR6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7544701-B2 Sulfonyldihydrobenzimidazolone compounds as 5-hydroxytryptamine-6 ligands WYETH (US) 2009-06-09 US claimed
EP-1654258-A1 SULFONYLDIHYDRO- BENZIMIDAZOLONE COMPOUNDS AS 5-HYDROXYTRYPTAMINE-6 LIGANDS Wyeth (US) 2006-05-10 EP claimed
WO-2005009996-A1 SULFONYLDIHYDRO- BENZIMIDAZOLONE COMPOUNDS AS 5-HYDROXYTRYPTAMINE-6 LIGANDS WYETH (US) 2005-02-03 WO claimed
US-20050020575-A1 Sulfonyldihydrobenzimidazolone compounds as 5-hydroxytryptamine-6 ligands WYETH (US) 2005-01-27 US claimed
US-7544701-B2 Sulfonyldihydrobenzimidazolone compounds as 5-hydroxytryptamine-6 ligands WYETH (US) 2009-06-09 US disclosed
US-7544701-B2 Sulfonyldihydrobenzimidazolone compounds as 5-hydroxytryptamine-6 ligands WYETH (US) 2009-06-09 US disclosed
US-7544701-B2 Sulfonyldihydrobenzimidazolone compounds as 5-hydroxytryptamine-6 ligands WYETH (US) 2009-06-09 US disclosed
EP-1654258-A1 SULFONYLDIHYDRO- BENZIMIDAZOLONE COMPOUNDS AS 5-HYDROXYTRYPTAMINE-6 LIGANDS Wyeth (US) 2006-05-10 EP disclosed
WO-2005009996-A1 SULFONYLDIHYDRO- BENZIMIDAZOLONE COMPOUNDS AS 5-HYDROXYTRYPTAMINE-6 LIGANDS WYETH (US) 2005-02-03 WO disclosed
US-20050020575-A1 Sulfonyldihydrobenzimidazolone compounds as 5-hydroxytryptamine-6 ligands WYETH (US) 2005-01-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050020575-A1 Sulfonyldihydrobenzimidazolone compounds as 5-hydroxytryptamine-6 ligands HTR6, HTR5A, HTR1B HTR6 1/4885PKM 1473/4885MCOLN3 2795/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.